Palbociclib (PD-0332991) HCl

Licensed by Pfizer Catalog No.S1116

Palbociclib (PD-0332991) HCl Chemical Structure

Molecular Weight(MW): 483.99

Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

Size Price Stock Quantity  
USD 110 In stock
USD 170 In stock
USD 570 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

6 Customer Reviews

  • PD-0332991 causes inhibition of proliferation of EAC cells in a dose-dependent manner. Western blots showing the phosphorylation status of pRB at Ser780 and Ser795 after incubation with 125 nmol/L PD-0332991 for 24 and 72 hours. Reduction in cyclin A expression and the expression of RB2 (p130) tumor suppressor 72 hours after PD-0332991 treatment are shown (bottom). Total pRB (RB1) and actin are loading controls and T293 cell lysate (293) is a positive control for total pRB and phospho-pRB (Ph-RB). E, anchorage-independent growth of the 3 cell lines in the presence or absence (Cnt) of 125 nmol/L PD-0332991 for 3 weeks.

    Clin Cancer Res 2011 17(13), 4513-22. Palbociclib (PD-0332991) HCl purchased from Selleck.

     

    Patient tumor cell sensitivity to combinatorial treatment with histone deacetylase (HDAC)/cyclin-dependent kinase (CDK) inhibitors in 3-D culture. The effect of each drug or drug combination was assessed by fluorescent dye to identify live (green) and dead cells (red). Cells from breast reduction patients were used as non-cancer control in the assay.

    Pharmacogenomics J 2013 13(1), 94-104. Palbociclib (PD-0332991) HCl purchased from Selleck.

  •  

    Cdk4 is upregulated in ARMS and mMSCs transfected with PAX7-FKHR fusion gene (MP7F), and can be specifi cally inhibited. D: IF results showing overexpression of cdk4 in MP7F cells compared to parental mMSCs and reduced expression of cdk4 after treatment of MP7F cells with the cdk4 inhibitor, PD-0332991. E: IF results showing MyoD1 expression in parental mMSCs cells, and MP7F cells untreated and after treatment with the cdk4 inhibitor, PD-0332991.

    Clin Transl Oncol 2012 14(3), 197-206 . Palbociclib (PD-0332991) HCl purchased from Selleck.

    WM3734 melanoma cells were treated by PD-0332991 for 36 hours; melanoma cells treated by Doxorubicin (DXR)  at 0.5 μM is included as a control.

     

     

    Dr. Gao Zhang of University of Pennsylvania. Palbociclib (PD-0332991) HCl purchased from Selleck.

  • Serum-deprived T98G glioma cells are restimulated with serum(FBS) with or without 1 μΜ PD-0332991.

     

     

    Dr. Sabine Paternot and Dr Pierre Roger of IRIBHM, ULB, Brussels. Palbociclib (PD-0332991) HCl purchased from Selleck.

    P16INK4A knockdown in INK4A/ARF-wt human glioma cell LN319 potentiates PDGF-Apromoted anchorage-dependent growth in vitro. Soft agar growth of Ink4a/Arf-deficient mAst and LN444 cells treated with PD0332991. (A) IB analysis. (B) Quantification of soft agar assays. β-actin was used as a loading control in all IB experiments. Data are presented as mean ± s.d. and representative of two independent experiments. **, P < 0.01; ***, P < 0.001

    Dr. Kun-Wei Liu from University of Pittsburgh. Palbociclib (PD-0332991) HCl purchased from Selleck.

Purity & Quality Control

Choose Selective CDK Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.
Features Non-cytotoxic, and halts cancer cell growth & could be used in glioblastoma that has relapsed after temozolomide treatment (a chemotherapeutic used to treat many cancers).
Targets
CDK4/CyclinD3 [1]
(Cell-free assay)
CDK4/CyclinD1 [1]
(Cell-free assay)
CDK6/CyclinD2 [1]
(Cell-free assay)
CDK2/CyclinE2 [1]
(Cell-free assay)
CDK2/CyclinA [1]
(Cell-free assay)
9 nM 11 nM 15 nM >10 μM >10 μM
In vitro

PD 0332991 has little effect on other protein kinases including EGFR, FGFR, PGFR, IR. PD 0332991 is a non-ATP competitive inhibitor of Cdk4. PD 0332991 inhibits MDA-MB-435 breast carcinoma cells with IC50 of 66 nM, which is due to reduced Rb phosphorylation at Ser780. PD 0332991 inhibits thymidine incorporation into the DNA of Rb-positive human breast, colon, and lung carcinomas as well as human leukemias, with IC50 values ranging from 0.04-0.17 μM. PD 0332991 shows no activity in Rb-negative cells. PD 0332991 causes an accumulation of cells in G1 in MDA-MB-453 breast and Colo-205 carcinoma cells. [1] PD 0332991 also shows activity in 5T33MM myeloma cells (immunocompetent model) and sensitizes the cells to killing by bortezomib. [2] PD 0332991 inhibits luminal ER-positive as well as HER2-amplified breast cancer cell lines including MDA-MB-175, ZR-75-30, CAMA-1, MDA-MB-134, HCC-202 and UACC-893. PD 0332991 enhances the activity of tamoxifen and trastuzumab in these cell lines. PD 0332991 enhances the sensitivity of tamoxifen in the MCF7 tamoxifen-resistant cells. [3] A recent study shows that PD 0332991 could suppress malignant rhabdoid tumor (MRT) cell lines including MP-MRT-AN, KP-MRT-RY, G401, KP-MRT-NS and the sensitivity of the MRT cell lines to PD 0332991 is inversely correlated with expression of p16. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MOLM13 NVvufGFGU2mwYYPlJGF{e2G7 MmPVNlQhcA>? MlzmTY5pcWKrdHnvckBw\iCFRFu0JIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gVoIheGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iByLkCwNkDPxE1? M{PWelI1PjRzMUCz
COLO205 NXLtTHM{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4W2e|czKGh? MYHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5Nme3OnZDDhd{BqdmOxcoDvdoF1cW:wIH;mJHs{UF22aIntbYRqdmViaX70c{BFVkFid3n0bEBKSzVyIH;mJFAvODN4IN88US=> NWixPGtJOjR4NEGxNFM>
U937 Mlz1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXv1blZ6PzJiaB?= Ml\YRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{\XO|ZXSgZZMhcW6lb4Lwc5JifGmxbjDv[kBcO0ifdHj5cYllcW6nIHnueI8hTE6DIIfpeIghUUN3MDDv[kAxNjF2IN88US=> NIrsWYYzPDZ2MUGwNy=>
MOLM13 NFvoR4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWK3NkBp MlGwRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPT1zNNVMh[2WubIOgbIFz[m:{aX7nJGZNXDNiSWTEJI12fGGwdDDhd5Nme3OnZDDhd{BqdmOxcoDvdoF1cW:wIH;mJHs{UF22aIntbYRqdmViaX70c{BFVkFid3n0bEBKSzVyIH;mJFAvODl4IN88US=> M33HU|I1PjRzMUCz
MOLM13 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PrS|czKGh? M1rpNmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4Sgd49z[W[nbnniMZJme2m|dHHueEBpfW2jbjDNU2xOOTNiY3XscJMh[XO|ZYPz[YQh[XNiaX7jc5Jxd3KjdHnvckBw\iCdM1jdeIh6dWmmaX7lJIlvfG9iRF7BJJdqfGhiSVO1NEBw\iByLkC5OkDPxE1? NVLrWJQzOjR4NEGxNFM>
MDA-MB-435 NEXjVXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\1XHFlOjRiaB?= M2HOXGlEPTB;MD6xOkDPxE1? M3SzelE2QDBzOEOx
K562 MY\DfZRwfG:6aXOgRZN{[Xl? Mn\aPVYhcA>? M37iOmROW09? M4XTWmlEPTB;MjFOwG0> MoH4NlQ1OTd3Nk[=
DU145 NHfueoZEgXSxdH;4bYMhSXO|YYm= NV\pVFZlQTZiaB?= NFLpTJVFVVOR M{jyXmlEPTB;Nz61JO69VQ>? NFe3NXIzPDRzN{W2Oi=>
MDA-MB-231 MoDSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYH2PVRiOSEQvF2= M2j0PFI1KGh? NEf0XlNFVVOR MVrD[YxtKGO7Y3zlJIFzemW|dDDhd5Nme3OnZDDhd{Bi[2O3bYXsZZRqd25iYYSgS|EheGijc3W= NV[2eVI5OjR2MUe1OlY>
MCF7 NXzkRoRRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHx[o0yKM7:TR?= NWr3dm5nOjRiaB?= MnPvSG1UVw>? M1:yfGNmdGxiY4njcIUh[XK{ZYP0JIF{e2W|c3XkJIF{KGGlY4XteYxifGmxbjDheEBIOSCyaHHz[S=> NH64TW4zPDRzN{W2Oi=>
MCF7 NY[xb2dLU2mwYYPlJGF{e2G7 MUS1JO69VQ>? M4nhR|I1KGh? M3H3bmROW09? NHyxOolKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JGNFUzRxY4njcIlvTDFiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iC{ZYTpco9jdGG|dH;tZUBxcG:|cHjvdplt[XSrb36gZZQhW2W{N{iw NV\DenYzOjR2MUe1OlY>
MDA-MB-231 NE\aNIhMcW6jc3WgRZN{[Xl? NHjuUHo2KM7:TR?= MVSyOEBp NUjVUmV1TE2VTx?= M3HLfWlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgR2RMPC:leXPsbY5FOSCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHKndHnuc4Jt[XO2b33hJJBpd3OyaH;yfYxifGmxbjDheEBU\XJ5OEC= NVfyU5VOOjR2MUe1OlY>
MDA-MB-231 NEDLToxHfW6ldHnvckBCe3OjeR?= MY[xMVExKM7:TR?= NVzON4s{OjRiaB?= MYTEUXNQ M3vuUYRw\XNibn;0JIlv\HWlZTDhdI9xfG:|aYOgZZN{\XO|ZXSgZZMhWEGUUDDjcIVifmGpZR?= NYno[|VyOjR2MUe1OlY>
MCF7 MULGeY5kfGmxbjDBd5NigQ>? MWmxMVExKM7:TR?= NF65NFAzPCCq M2\tbWROW09? MWPkc4V{KG6xdDDpcoR2[2ViYYDvdJRwe2m|IHHzd4V{e2WmIHHzJHBCWlBiY3zlZZZi\2V? MWKyOFQyPzV4Nh?=
MDA-MB-231 M1jJPGZ2dmO2aX;uJGF{e2G7 MWGwMlUuOSEQvF2= Ml2wOFghcA>? NUPhb3YzTE2VTx?= M3u2fohieyCwbzDD[YxtKGO7Y3zlJIFzemW|dDDhd5Nme3OnZDDhd{Bi[2O3bYXsZZRqd25iYYSgd5VjNUdzIIDoZZNm MmL6NlQ1OTd3Nk[=
MCF7 MlrLSpVv[3Srb36gRZN{[Xl? M3zJbVAvPS1zIN88US=> NEPReIw1QCCq MVrEUXNQ NGS1OWpp[XNibn:gR4VtdCCleXPs[UBienKnc4SgZZN{\XO|ZXSgZZMh[WOldX31cIF1cW:wIHH0JJN2[i2JMTDwbIF{\Q>? NEjvTmczPDRzN{W2Oi=>
697 NU\3RnZNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\nTWM2OD1zNEiuN|ghdk1? M2X4fXNCVkeHUh?=
P12-ICHIKAWA M2foR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnhWXBJUUN3ME25Ok4xPCCwTR?= NEP5N5hUSU6JRWK=
NB69 NIi0eldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXDWotKSzVyPUG2NU45KG6P MVjTRW5ITVJ?
EoL-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFOwRmpKSzVyPUG4O{4zPiCwTR?= MWrTRW5ITVJ?
BHT-101 M3\HZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\ZenRyUUN3ME2xPVgvOjVibl2= MmC2V2FPT0WU
SK-NEP-1 NY\QcVB4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTJ{MD6wNkBvVQ>? M1XzR3NCVkeHUh?=
MHH-NB-11 NFzUV|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MluzTWM2OD1{MkCuNVkhdk1? NGr5d|lUSU6JRWK=
AsPC-1 MknWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LhUWlEPTB;MkWyMlU{KG6P M37qNHNCVkeHUh?=
ES1 M3[xNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkK4TWM2OD1{NU[uNlUhdk1? MUTTRW5ITVJ?
LAMA-84 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTJ3OD6xPUBvVQ>? MV;TRW5ITVJ?
MOLT-16 Mn7HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33LTGlEPTB;MkW4MlQ6KG6P NInjNYdUSU6JRWK=
ES7 NXLyUm42T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjxcIVKSzVyPUK3N{4xQSCwTR?= MYfTRW5ITVJ?
KY821 NVf4dXZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTNzND6xJI5O MUPTRW5ITVJ?
RT-112 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITJTXlKSzVyPUOyNU4xPSCwTR?= MmnmV2FPT0WU
HL-60 NFLEeXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7oUHFKSzVyPUO0NE43PiCwTR?= M2jS[HNCVkeHUh?=
MOLT-4 M1;QVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nYcmlEPTB;M{S1MlE{KG6P NX:0bJZ3W0GQR1XS
KARPAS-45 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLEUFlDUUN3ME2zO|YvOTZibl2= MmDhV2FPT0WU
SK-N-AS NWi2N3J4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFKxbHJKSzVyPUO4O{45OyCwTR?= NYnNV4tbW0GQR1XS
CTB-1 NHvMSGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTRyNT6wNkBvVQ>? M4\YNnNCVkeHUh?=
NKM-1 NGHad3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXFWIFMUUN3ME20NVEvQDlibl2= NUS4OJB1W0GQR1XS
HTC-C3 MlvtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLBTWM2OD12M{KuPVUhdk1? NGq0Z2NUSU6JRWK=
BE-13 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1H6ZmlEPTB;NES0MlI4KG6P MoqxV2FPT0WU
KOSC-2 NULhdZZLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1G5OmlEPTB;NE[2Mlkhdk1? MYDTRW5ITVJ?
NB14 NEfWXYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jtXGlEPTB;NEizMlU5KG6P M1rYWnNCVkeHUh?=
CAL-27 NH3GTotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTR7ND61PUBvVQ>? NUPlXnR[W0GQR1XS
H9 NXvofXpjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHqwZoJKSzVyPUS5OU41OyCwTR?= MkPvV2FPT0WU
RS4-11 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{T3R2lEPTB;NUC0Mlc{KG6P Mlj6V2FPT0WU
PA-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3i[mVqUUN3ME21NFkvQDZibl2= M{H2OXNCVkeHUh?=
MV-4-11 NH3xOXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTVzMz64OUBvVQ>? MmjyV2FPT0WU
OS-RC-2 NUL3RnNmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3VPG1KSzVyPUWyNU43OiCwTR?= M{LkdXNCVkeHUh?=
RPMI-8226 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfmXmtKSzVyPUWyOk45PiCwTR?= M1XqWHNCVkeHUh?=
HGC-27 M4rQPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mor0TWM2OD13NkSuPVkhdk1? NYrBWopYW0GQR1XS
CHP-212 NWPWXIdnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLmTWM2OD13OUOuOVkhdk1? M2CxWXNCVkeHUh?=
NB10 NEHGNI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M12z[2lEPTB;NUm5MlE5KG6P NX7SXJpyW0GQR1XS
HH NGPKSlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIS5ZVlKSzVyPUW5PU41OyCwTR?= NUXzWHFwW0GQR1XS
EW-16 MlWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\PTWM2OD14MEOuOVIhdk1? NV31XZpEW0GQR1XS
ES8 NEDDbnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnKxTWM2OD14MEWuNlEhdk1? M{XTcXNCVkeHUh?=
HAL-01 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTZyNT62O{BvVQ>? M1XBRnNCVkeHUh?=
A204 NFKweohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlq4TWM2OD14M{OuPVEhdk1? M2K5[XNCVkeHUh?=
MHH-PREB-1 MlXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7lTWM2OD14M{[uPVkhdk1? MUPTRW5ITVJ?
EM-2 NX75U3hpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7BVIRNUUN3ME22OVAvPjRibl2= NGqycVFUSU6JRWK=
BV-173 M3vqVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjmUIVKSzVyPU[1Nk41QCCwTR?= M3LYSnNCVkeHUh?=
ONS-76 MmLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITad2VKSzVyPU[3O{45OiCwTR?= NUPzcFhjW0GQR1XS
KM-H2 NH\kSphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37QUGlEPTB;Nkm1MlU1KG6P NEX0UYNUSU6JRWK=
D-263MG MnvNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTkV4NSUUN3ME23NVcvOTJibl2= NID4cXJUSU6JRWK=
ES3 NYrBPVJVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLPeHc3UUN3ME23NlgvQTNibl2= M3W5VXNCVkeHUh?=
VA-ES-BJ NGTsSFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mly0TWM2OD15M{KuNlchdk1? Mn\6V2FPT0WU
NBsusSR NYfHOlNZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXFUJlKSzVyPUe0Nk46QSCwTR?= NXvhUnZyW0GQR1XS
NCI-H520 NGjVb3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DkemlEPTB;N{S2MlUzKG6P MnPFV2FPT0WU
ES5 NIDsc3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HO[2lEPTB;N{WyMlghdk1? NEn4c3FUSU6JRWK=
T-24 MkXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTd5OD63NUBvVQ>? MnXNV2FPT0WU
SW962 NVHQdVkzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rrTWlEPTB;OEC4MlY{KG6P NGXLfppUSU6JRWK=
EW-3 MlfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDRbY06UUN3ME24NFgvPzZibl2= MlXvV2FPT0WU
RXF393 MmLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRThzMj63PUBvVQ>? M4CxZ3NCVkeHUh?=
U251 NHPRcJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTIcXBPUUN3ME24NVMvQDhibl2= NHjwb4ZUSU6JRWK=
CAMA-1 M4jkUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrQTWM2OD16M{OuPVQhdk1? Ml\UV2FPT0WU
JVM-3 NXjpPIplT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTh3MT63PEBvVQ>? NFLJRWpUSU6JRWK=
COLO-800 MkHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnJeotQUUN3ME24PVcvPzhibl2= NU\jZnF2W0GQR1XS
OVCAR-5 NHXP[GFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPaTWM2OD17MECuNUBvVQ>? NEjlN4pUSU6JRWK=
LB1047-RCC NFXyVmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnT1TWM2OD17MkeuOVYhdk1? MVvTRW5ITVJ?
SW954 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofpTWM2OD17MkmuOFEhdk1? NWLKOWc4W0GQR1XS
J-RT3-T3-5 NVzsdWQyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTl|Nj6wOkBvVQ>? M3LDfnNCVkeHUh?=
Mewo Ml[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH:w[npKSzVyPUmzOk43KG6P MlfXV2FPT0WU
NCI-H1770 M{fPcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXr4dINnUUN3ME25OFAvPTVibl2= MmjxV2FPT0WU
HO-1-N-1 M1vqe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTl4Mj64NUBvVQ>? MkTyV2FPT0WU
HSC-3 NXPIfJY{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTl4Nj60PEBvVQ>? NYLBWId{W0GQR1XS
TYK-nu NXiyc2plT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLz[4ptUUN3ME25PVgvOjVibl2= NX7jWGhCW0GQR1XS
KYSE-150 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3uxSGlEPTB;MT6wNFA4PiEQvF2= MV3TRW5ITVJ?
SN12C MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjITWM2OD1zLkCwPFc2KM7:TR?= NYjxUlYyW0GQR1XS
MOLT-13 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkW1TWM2OD1zLkCxOFIyKM7:TR?= NFTNc|VUSU6JRWK=
TE-11 NX\KVotwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfNOXRKSzVyPUGuNFQ5OTJizszN M{\6cHNCVkeHUh?=
DB M2fye2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjLflk1UUN3ME2xMlA4Ojd|IN88US=> NFT5TGpUSU6JRWK=
CAL-39 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTFwMEe1NlIh|ryP Mof3V2FPT0WU
A3-KAW Mn[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEG4c3JKSzVyPUGuNFg1ODhizszN NWm3ZnZUW0GQR1XS
CHP-134 NIizVWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTFwMUG4NFch|ryP NHzBW2VUSU6JRWK=
TGW Ml;MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUi1fWh3UUN3ME2xMlEzOzl3IN88US=> M3HrPXNCVkeHUh?=
QIMR-WIL NVnkOW1LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTFwMUOxN|Qh|ryP NHLaZ49USU6JRWK=
NCI-SNU-1 MnTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTJTWM2OD1zLkG2N|U1KM7:TR?= M4HGd3NCVkeHUh?=
CGTH-W-1 NYO3ZoV6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfRTWM2OD1zLkG3NVg3KM7:TR?= MVHTRW5ITVJ?
MHH-ES-1 M2nZfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTFwMUe5PFYh|ryP Mlr1V2FPT0WU
LB2241-RCC NYHtcmo4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXXVZliUUN3ME2xMlE5PjJizszN MYHTRW5ITVJ?
ML-2 MmX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojjTWM2OD1zLkKwO|M1KM7:TR?= M17qVnNCVkeHUh?=
COR-L23 NXHZcYhoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXT6UZA1UUN3ME2xMlIzQTN|IN88US=> MkT3V2FPT0WU
BFTC-905 NWTZVFU2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTFwMkSyOlch|ryP MVLTRW5ITVJ?
Hs-578-T MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrpPYtKSzVyPUGuNlU5OTdizszN MWLTRW5ITVJ?
KG-1 NHqyOlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjHTnk1UUN3ME2xMlI3Pjh4IN88US=> MkTTV2FPT0WU
HEL NUDI[mlDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTFwMkmzN|gh|ryP NYr0OVY2W0GQR1XS
A549 Mke0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknHTWM2OD1zLkK5N|k6KM7:TR?= MY\TRW5ITVJ?
COLO-741 MnfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnGwTWM2OD1zLkOyNFg6KM7:TR?= MV3TRW5ITVJ?
PC-3 NGXYdnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3aTWM2OD1zLkO1NlIyKM7:TR?= M2nITXNCVkeHUh?=
HOS NHK3eWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2L4NmlEPTB;MT6zOVI6PiEQvF2= NXvUdmJrW0GQR1XS
HT-1080 MnTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvpTWM2OD1zLkO3OVE6KM7:TR?= NI\SeI5USU6JRWK=
TE-8 NGLUWG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4Pue2lEPTB;MT60NVc4PCEQvF2= NVrad2ZtW0GQR1XS
BHY MnPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPtS4FKUUN3ME2xMlQ3QTJ|IN88US=> M4fSSHNCVkeHUh?=
BB65-RCC M3uyZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{OyemlEPTB;MT61NFUzQCEQvF2= NX;NUoQ3W0GQR1XS
HN M4XL[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjrPZdrUUN3ME2xMlU1ODdzIN88US=> MUPTRW5ITVJ?
NCI-H441 Mn3JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTFwNUS5NFch|ryP NV;W[XNLW0GQR1XS
RPMI-8866 NVv0Z5p{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlyyTWM2OD1zLkW4OVA4KM7:TR?= NIS5dnZUSU6JRWK=
CAL-62 NYLEd3ZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M12yWWlEPTB;MT62NFg3OiEQvF2= M{T4fHNCVkeHUh?=
MG-63 NXT3RZRZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml20TWM2OD1zLk[xPFE{KM7:TR?= M{HGZ3NCVkeHUh?=
SK-LU-1 NF;zVHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\OTWM2OD1zLk[yNVUzKM7:TR?= Mm\hV2FPT0WU
BCPAP MoXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;LbpJFUUN3ME2xMlY3PDV5IN88US=> M{HDS3NCVkeHUh?=
22RV1 NIP6XnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXFUJVKSzVyPUGuOlc5PDNizszN NWKy[mxlW0GQR1XS
T47D M1HxOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGO3VYhKSzVyPUGuOlgxPjFizszN MYDTRW5ITVJ?
MSTO-211H NFnGTIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1O5S2lEPTB;MT62PVYxOyEQvF2= Ml3SV2FPT0WU
DEL M2nLWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPHSYpKSzVyPUGuO|AzPzNizszN M4HVPXNCVkeHUh?=
H4 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYG0b2JHUUN3ME2xMlc{OjF{IN88US=> M{HCVHNCVkeHUh?=
CAL-51 NWTJV3lqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTETWM2OD1zLke0PFU2KM7:TR?= Mn[yV2FPT0WU
ABC-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1j2OGlEPTB;MT63PFU5OiEQvF2= MWTTRW5ITVJ?
MZ2-MEL MmflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjk[4FKSzVyPUGuO|k2PDJizszN NWna[ohSW0GQR1XS
YKG-1 Mmi2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLRTWM2OD1zLkixNFYyKM7:TR?= NWjTc21LW0GQR1XS
KM12 NILYU21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHPRo1QUUN3ME2xMlgyPjB{IN88US=> NIjmeXVUSU6JRWK=
L-363 NVjOc|BRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTFwOEe0NVIh|ryP NUmwZpNMW0GQR1XS
KU812 M374[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nJTWlEPTB;MT64PVI5OiEQvF2= NWjkVlB3W0GQR1XS
LOXIMVI NGfabWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\Ud2lEPTB;MT65NVIzQCEQvF2= M1O2NXNCVkeHUh?=
G-401 NHLlXHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGWwW2xKSzVyPUGuPVI1OjhizszN NUHEdotQW0GQR1XS
SW780 NUn5PVJiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHVfY1KSzVyPUGuPVYzPDZizszN MXvTRW5ITVJ?
SW872 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;kc2lEPTB;MT65PFM{KM7:TR?= M3vFdHNCVkeHUh?=
NB7 NIX6cmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTFwOUmzNlMh|ryP MWXTRW5ITVJ?
T98G NIe1cpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17zW2lEPTB;Mj6wNFY3PiEQvF2= Mkf0V2FPT0WU
SW1710 NHHWXmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTJwME[5OFUh|ryP MoqyV2FPT0WU
NCI-H1573 NH;X[G1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTJwMEeyPVgh|ryP M2HuT3NCVkeHUh?=
KE-37 NGLOS3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTJwMEi5OVEh|ryP Mn\GV2FPT0WU
786-0 MnXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTJwMUW0N|kh|ryP MlXTV2FPT0WU
SAS NVvqUplnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4i5WGlEPTB;Mj6yNFM4PCEQvF2= M{DYVXNCVkeHUh?=
CAL-54 NVz5XGpET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmOzTWM2OD1{LkKwOFE{KM7:TR?= M{LnTXNCVkeHUh?=
SF268 MlHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;oVnlKSzVyPUKuNlMyOjJizszN MlvlV2FPT0WU
SW620 M3fHdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\GbGlEPTB;Mj6yOlE3QSEQvF2= MWfTRW5ITVJ?
MN-60 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\LZmlEPTB;Mj6zNVA3KM7:TR?= NH7zXphUSU6JRWK=
EFO-27 M2jlU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTJwM{KwOVgh|ryP NHLVV3hUSU6JRWK=
NCI-H747 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3hTWM2OD1{LkOyNVk6KM7:TR?= M2SwTnNCVkeHUh?=
HCC2218 NVy5dmQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzUTWM2OD1{LkO1N|c1KM7:TR?= MoTUV2FPT0WU
MIA-PaCa-2 NWnIXoVWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjMTWM2OD1{LkO2OFM4KM7:TR?= MVrTRW5ITVJ?
SJSA-1 NVvYe|VuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfGc|ZFUUN3ME2yMlM4Pzl4IN88US=> MWLTRW5ITVJ?
RKO M{TZS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DQZ2lEPTB;Mj6zPFQ6PiEQvF2= MXrTRW5ITVJ?
NB6 M{fvPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHyNY1KSzVyPUKuOFA{PzRizszN NGHHeWtUSU6JRWK=
ES4 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7iTWM2OD1{LkS1OFIzKM7:TR?= Mn65V2FPT0WU
EGI-1 M3TsXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTJwNE[4PFMh|ryP MlH0V2FPT0WU
CTV-1 MmPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTJwNUK3O|Mh|ryP NFLYbYlUSU6JRWK=
NCI-H1355 MoDUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;4TWM2OD1{LkW1PVUyKM7:TR?= NXq2ZVkxW0GQR1XS
GT3TKB NUfKdIFoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnPO2JYUUN3ME2yMlU6OTl7IN88US=> MlXBV2FPT0WU
SK-HEP-1 M2TCfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XqZ2lEPTB;Mj61PVI3PiEQvF2= NWX5bVZHW0GQR1XS
GAMG M4ThdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFztTldKSzVyPUKuOVk{QTRizszN Mk\QV2FPT0WU
SK-MES-1 NX;XcpZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYW0U5A5UUN3ME2yMlYyQDB|IN88US=> MX;TRW5ITVJ?
RO82-W-1 M{PFbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTJwNkKwOVch|ryP NHX2RoVUSU6JRWK=
ECC10 MkjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTJwN{CyNFYh|ryP NGDjXGZUSU6JRWK=
MCF7 MojKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{faSWlEPTB;Mj63NVQ3PCEQvF2= M1e0[3NCVkeHUh?=
D-283MED Mn:2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{W0TmlEPTB;Mj63NlQ{KM7:TR?= MnrMV2FPT0WU
RPMI-7951 NIPPVG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzJcG1{UUN3ME2yMlc2Pjl2IN88US=> NX3TXGdCW0GQR1XS
Ramos-2G6-4C10 M3fKO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\wTWM2OD1{Lke3NFk6KM7:TR?= NGL2dmNUSU6JRWK=
KGN MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LUNmlEPTB;Mj64NVg5PCEQvF2= NFjUSYxUSU6JRWK=
NUGC-3 M1nJfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jRUmlEPTB;Mj64NlUxPSEQvF2= M2LPd3NCVkeHUh?=
NCI-H292 NUK0S3FrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXHRpBUUUN3ME2yMlg2ODV|IN88US=> MXPTRW5ITVJ?
Becker Ml;oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{Xsb2lEPTB;Mj65OVg{OiEQvF2= M2DtRnNCVkeHUh?=
NCI-H1299 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTJW4xKSzVyPUOuNFUzPjNizszN M4njUXNCVkeHUh?=
ETK-1 M37IbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrGZnJJUUN3ME2zMlA2PDNizszN Mn;HV2FPT0WU
TK10 NVW1PWZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfZUHNEUUN3ME2zMlIxOTZ3IN88US=> NEXZWXJUSU6JRWK=
VMRC-RCZ MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\wS|hKSzVyPUOuN|Y1QDhizszN MXzTRW5ITVJ?
YH-13 M{LQTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTNwNESwO|kh|ryP Ml3SV2FPT0WU
DU-145 M3G5fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3RTWM2OD1|LkS2NlY6KM7:TR?= NHXDc|FUSU6JRWK=
SW1088 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4GxUGlEPTB;Mz60O|Q4KM7:TR?= M3zmR3NCVkeHUh?=
HOP-92 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTNwNUCzOFIh|ryP NXi0RolzW0GQR1XS
KP-N-YS NHjnUo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTNwNkKxN|kh|ryP MXrTRW5ITVJ?
NCI-H460 Mm\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmCyTWM2OD1|Lk[2O|Mh|ryP NWfXc41pW0GQR1XS
U-2-OS MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3nXWdKSzVyPUOuO|I2OzVizszN MY\TRW5ITVJ?
A101D NHnZUYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVO1UYl{UUN3ME2zMlc3QTN4IN88US=> M{\PdnNCVkeHUh?=
MDA-MB-231 NWW0TIhkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTNwOEG5OVEh|ryP MlPHV2FPT0WU
IST-MES1 NYrzXHBiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVK3ZldNUUN3ME2zMlg{OiEQvF2= NUKzdYw4W0GQR1XS
COR-L105 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fQWmlEPTB;ND6wNVgh|ryP Mo\MV2FPT0WU
NCI-H1437 MmTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjwfWZKSzVyPUSuNFI{ODJizszN MoOyV2FPT0WU
CAL-85-1 NVT1eFl5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jLc2lEPTB;ND6wNlQ3OSEQvF2= MWTTRW5ITVJ?
MZ1-PC NUHzeFV3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLEZZFKSzVyPUSuNVg2PTZizszN M2H4[XNCVkeHUh?=
VM-CUB-1 NF;XT5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFniTYtKSzVyPUSuN|EzQDRizszN NILJUoNUSU6JRWK=
CHL-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjaOYFXUUN3ME20MlMzOTZ7IN88US=> NV;3SndRW0GQR1XS
MDA-MB-361 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofyTWM2OD12LkOzNVU{KM7:TR?= MlLGV2FPT0WU
NCI-H661 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3z6TWlEPTB;ND61NFA6OiEQvF2= Ml32V2FPT0WU
EW-11 NX\HVGNbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTRwNUKyN|Eh|ryP NFK1XFdUSU6JRWK=
BEN M{jVOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTRwNUK4NVUh|ryP MYTTRW5ITVJ?
BFTC-909 NIfDdHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrvfHZKSzVyPUSuOVYzPzVizszN NFnBWJFUSU6JRWK=
NCI-H2087 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX34SFI1UUN3ME20MlU5OTZ2IN88US=> MVjTRW5ITVJ?
RVH-421 NXH2RotvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zKcWlEPTB;ND62OlY6KM7:TR?= MWLTRW5ITVJ?
P30-OHK M{\Ybmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rBZWlEPTB;ND62PFAxQCEQvF2= MmjMV2FPT0WU
NCI-H28 MmXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFGzR5hKSzVyPUSuPFE3PjFizszN NXT1dnZ1W0GQR1XS
ES6 Mmi2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInITHhKSzVyPUSuPFMxOTZizszN NHLIT5RUSU6JRWK=
769-P MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTRwOEW5NlYh|ryP NIP2eFFUSU6JRWK=
OE33 M{XHRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTRwOEixOlEh|ryP NGH5SWNUSU6JRWK=
SW982 M3PWcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\mPI05UUN3ME20Mlk2ODZzIN88US=> NEjXV41USU6JRWK=
A388 M2ftXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXXepBGUUN3ME21MlAzQTh|IN88US=> M{jucnNCVkeHUh?=
TI-73 NELvcXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofwTWM2OD13LkC2NVk1KM7:TR?= M{f5SnNCVkeHUh?=
HCT-116 NV;NcGhYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DIWWlEPTB;NT6wPVg5QSEQvF2= MmHOV2FPT0WU
HuP-T3 M1\DO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7CTWM2OD13LkG4O|A6KM7:TR?= M4DhTnNCVkeHUh?=
G-402 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfQSolbUUN3ME21MlE6PDF4IN88US=> M1WwTnNCVkeHUh?=
NCI-H1792 M4rHOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTVwMkS2NlIh|ryP NVztdHNkW0GQR1XS
NCI-H209 M4nHemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjxWnV4UUN3ME21MlI2QTR{IN88US=> NUC4OJc{W0GQR1XS
NCI-H1650 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\tTWM2OD13LkOwOlM1KM7:TR?= M1HjNnNCVkeHUh?=
LCLC-97TM1 MoTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml76TWM2OD13LkOxPFA5KM7:TR?= MkLpV2FPT0WU
S-117 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3sPZpqUUN3ME21MlM3QTd4IN88US=> MXjTRW5ITVJ?
GI-ME-N MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDySnNKSzVyPUWuN|k3QDFizszN NUTJZWxTW0GQR1XS
NCI-H2122 NYHCVYMyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXe1Sm9YUUN3ME21MlQ6Ozl5IN88US=> NVjjTWFVW0GQR1XS
NCI-H1793 M2HUfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PZV2lEPTB;NT62O|U6OyEQvF2= M3HJe3NCVkeHUh?=
C2BBe1 NVjLbXhTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHH4OoZKSzVyPUWuO|AxQDhizszN NGnHfpdUSU6JRWK=
TE-12 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTVwOEC1OVYh|ryP M33ZdXNCVkeHUh?=
LCLC-103H MnfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXGZmdKSzVyPUWuPVE4KM7:TR?= NVzyOoRNW0GQR1XS
A673 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTVwOUG5N|Ih|ryP MUXTRW5ITVJ?
BB30-HNC NH\jNo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTVwOUizOkDPxE1? NUXVdplTW0GQR1XS
SF295 NWC5ZoYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXsWJZKSzVyPU[uNFA1OjJizszN NILRZpRUSU6JRWK=
KU-19-19 M2LhR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHNTWM2OD14LkCxO|MyKM7:TR?= NGDyTo9USU6JRWK=
CFPAC-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XUUmlEPTB;Nj6wOFQ1OyEQvF2= NFPPVnFUSU6JRWK=
LoVo NFGxUGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fVVmlEPTB;Nj6wOVA3OyEQvF2= MUfTRW5ITVJ?
8505C MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTZwMEe1O|Mh|ryP MV;TRW5ITVJ?
GMS-10 NYS4OINqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXOyXJp[UUN3ME22MlE2ODB{IN88US=> NH\qNXdUSU6JRWK=
Ca9-22 M{nVV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV[xfYJVUUN3ME22MlE3PzFizszN M3f1dXNCVkeHUh?=
DOK M33rNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTZwMkKwO|Ih|ryP NFjWXoZUSU6JRWK=
FADU NWnVN5g4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHUPIUzUUN3ME22MlI3ODN7IN88US=> MljVV2FPT0WU
BxPC-3 NWXRcFlHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojETWM2OD14LkK3N|Ih|ryP Ml7rV2FPT0WU
CAL-33 NFTITJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPJTWM2OD14LkK5NlAyKM7:TR?= NH3ZeY5USU6JRWK=
SHP-77 M1G3WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLsOmJqUUN3ME22MlMyPTF{IN88US=> MX3TRW5ITVJ?
LXF-289 NHj3dXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LzZ2lEPTB;Nj6zN|Q2PSEQvF2= NHfMO4RUSU6JRWK=
GB-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWP5S5lXUUN3ME22MlM5OiEQvF2= NITTNHBUSU6JRWK=
KS-1 NXPNc2lGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LvRWlEPTB;Nj6zPFQ1PyEQvF2= M4q1bnNCVkeHUh?=
D-502MG MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITCdGxKSzVyPU[uOFI{PzZizszN M3LOb3NCVkeHUh?=
LAN-6 NVHM[XYyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTZwNUGwNlMh|ryP M3LGdnNCVkeHUh?=
H-EMC-SS MnzsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonDTWM2OD14LkW2NVQ4KM7:TR?= MkKwV2FPT0WU
LC-2-ad M1rCfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnweo1KSzVyPU[uOlAxPzZizszN M2HXeHNCVkeHUh?=
NCI-H1693 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjyfHVKSzVyPU[uOlIzOTVizszN NGH4dllUSU6JRWK=
SK-N-FI NXTaSIw4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnG3TWM2OD14Lke1NFQ1KM7:TR?= MnuwV2FPT0WU
D-423MG M2D3Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPXT3U4UUN3ME22Mlc3OTF5IN88US=> M{nTdXNCVkeHUh?=
KNS-42 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXnbopFUUN3ME22Mlc5OTl5IN88US=> MXvTRW5ITVJ?
GCT MlXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4K3[WlEPTB;Nj65N|gh|ryP M3;pUnNCVkeHUh?=
DSH1 Mn3ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIOzN5BKSzVyPUeuNFY{OyEQvF2= MVLTRW5ITVJ?
D-247MG NVrRZVZLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrpR3lVUUN3ME23MlA4QDhzIN88US=> MYjTRW5ITVJ?
NCI-SNU-5 NVrxWmE{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXWzWYxSUUN3ME23MlE5OzdzIN88US=> NUjYOmJnW0GQR1XS
TE-6 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXjTWM2OD15LkKwOlAyKM7:TR?= MVvTRW5ITVJ?
NOMO-1 MmDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2C5RWlEPTB;Nz6yNlEzPyEQvF2= NIDVZ5JUSU6JRWK=
NB17 NX;FWWxET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3iTWM2OD15LkOwN|A6KM7:TR?= M4rk[nNCVkeHUh?=
EW-22 NFH6PZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHuU4hKSzVyPUeuN|Q{PDhizszN MYHTRW5ITVJ?
EW-13 NHL4TIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTdwM{WxOlIh|ryP MlHqV2FPT0WU
DOHH-2 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3XVodKSzVyPUeuOFQxOiEQvF2= NUnie3VOW0GQR1XS
TGBC1TKB MmDVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LtbmlEPTB;Nz60PVg6QSEQvF2= MX3TRW5ITVJ?
GR-ST MnvCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTdwNUK1PVQh|ryP M1fSSnNCVkeHUh?=
KYSE-520 NIfk[o9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3m0dGlEPTB;Nz61OVUyPSEQvF2= M4C0dHNCVkeHUh?=
CAPAN-1 NWm1[VlMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzzTWM2OD15LkW5OVEh|ryP M2r3cnNCVkeHUh?=
HCE-4 NEnrVZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7LTWM2OD15Lk[yNlc6KM7:TR?= MXjTRW5ITVJ?
MLMA NFnXcpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fSVmlEPTB;Nz62Nlk2PyEQvF2= NVW2NJdXW0GQR1XS
HT-144 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLlWopzUUN3ME23MlY2OzZ6IN88US=> NXHzPGgyW0GQR1XS
KYSE-180 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;tTWM2OD15LkexNVY6KM7:TR?= NY[yR4t7W0GQR1XS
TE-5 M3nPd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1v1Z2lEPTB;Nz65OVk4OSEQvF2= NUe3cphpW0GQR1XS
IGROV-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HsU2lEPTB;Nz65PFU2OSEQvF2= NFW0UpRUSU6JRWK=
NCI-H1581 M4L1T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfKTWM2OD16LkCxNkDPxE1? MVjTRW5ITVJ?
SW1990 M1[3[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoCzTWM2OD16LkC0OlU6KM7:TR?= NVH4e3k3W0GQR1XS
EFM-19 NHLJ[lhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DQfWlEPTB;OD6wPFU1PSEQvF2= NWTYcoRzW0GQR1XS
OGR-1 M1;0TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LLOmlEPTB;OD60N|AzOyEQvF2= MYLTRW5ITVJ?
U-118-MG M4\kUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGi1RpBKSzVyPUiuOFM1PjNizszN M1HyNnNCVkeHUh?=
SK-OV-3 Mn3KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zIWmlEPTB;OD60Olc3PSEQvF2= M{DwXHNCVkeHUh?=
KNS-62 NHzZfXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjjdmx{UUN3ME24MlUyPzZzIN88US=> MYXTRW5ITVJ?
GOTO M2PzZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRThwNUe2N|Uh|ryP M3rNdXNCVkeHUh?=
8305C MonBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjwbot6UUN3ME24MlcxPDh2IN88US=> M1z0WHNCVkeHUh?=
RPMI-2650 M1f2WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRThwN{G5OVUh|ryP MlPwV2FPT0WU
NEC8 MnXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\pc3pnUUN3ME24Mlc1OzB5IN88US=> NVfocZh6W0GQR1XS
KYSE-450 Mk\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXlbWRUUUN3ME24Mlg3PTR6IN88US=> MULTRW5ITVJ?
RMG-I NGrq[mdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTlwMUSwOVgh|ryP NH3lfW5USU6JRWK=
CAKI-1 M{nOSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTlwM{G5O|kh|ryP MU\TRW5ITVJ?
KYSE-510 Mk[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTlwM{W3O|gh|ryP MUjTRW5ITVJ?
A4-Fuk NYrPVZh7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlX5TWM2OD17LkO2O|AyKM7:TR?= NXnBZmtHW0GQR1XS
AN3-CA MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTlwNEW0OFQh|ryP MV7TRW5ITVJ?
SK-N-DZ NVz0fld3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4K4dGlEPTB;OT63Nlg1QSEQvF2= M{jJfHNCVkeHUh?=
HSC-2 NGPNeXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDrPJhJUUN3ME25Mlc3PjJ7IN88US=> NH\xb25USU6JRWK=
EW-1 NH\E[GlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXxN5ZDUUN3ME25Mlc6OzZ7IN88US=> NIr5V29USU6JRWK=
D-566MG NXjVWG1ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHEfG9FUUN3ME25Mlg{PjZ2IN88US=> M4nSWHNCVkeHUh?=
COLO-792 NHS0eIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTlwOUi3OFYh|ryP MnfnV2FPT0WU
TE-10 Mk\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrxPFZiUUN3ME2xNE4xOzl4IN88US=> NHr5WWdUSU6JRWK=
NCI-H650 M4jUR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LsOWlEPTB;MUCuOFI5PiEQvF2= NGDrdZdUSU6JRWK=
U-266 NF;BdIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTFyLkS1OUDPxE1? NUn3cW1EW0GQR1XS
Detroit562 MnW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LKVGlEPTB;MUGuNFUyPSEQvF2= MUHTRW5ITVJ?
NH-12 NUTrZVN7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLlc3F3UUN3ME2xNU4yPDR4IN88US=> MVzTRW5ITVJ?
CO-314 Mke4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPEU2pKSzVyPUGxMlI5PDJizszN NI\NWoNUSU6JRWK=
IST-MEL1 MlvtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nxNmlEPTB;MUGuOVMzOyEQvF2= MmDBV2FPT0WU
KNS-81-FD NWPpeWVjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvvTWM2OD1zMT61OVI4KM7:TR?= MoP3V2FPT0WU
SW1463 NIXT[VlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHWe5BxUUN3ME2xNU42QTh7IN88US=> NETHOHZUSU6JRWK=
NCI-H23 NIXHUFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37uS2lEPTB;MUGuOlU2OiEQvF2= MWnTRW5ITVJ?
SK-MEL-2 NID4b2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYm0OYdMUUN3ME2xNU44OTl5IN88US=> M4\LNXNCVkeHUh?=
NB13 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorMTWM2OD1zMj6xOFk2KM7:TR?= MlvnV2FPT0WU
Daoy NYPpTm51T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4foVGlEPTB;MUKuNlg2PiEQvF2= NFyydXlUSU6JRWK=
NCI-H1623 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTrdYhMUUN3ME2xNk4{QDBzIN88US=> NHHHSGRUSU6JRWK=
NMC-G1 NUHJT2dyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHleWtuUUN3ME2xNk44OTdizszN MY\TRW5ITVJ?
DK-MG NFLZfJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3ITWM2OD1zMj65OFgzKM7:TR?= M1Hxd3NCVkeHUh?=
TCCSUP NEPTbZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTF|LkGyPFQh|ryP MX;TRW5ITVJ?
SCC-15 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTF|LkK2OVEh|ryP MWfTRW5ITVJ?
NOS-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTF|LkK4PVMh|ryP NFKyXIlUSU6JRWK=
RH-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrkXItKSzVyPUGzMlMxOzdizszN NIH4N4pUSU6JRWK=
SK-MEL-3 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfMcIt2UUN3ME2xN{4{PzJ6IN88US=> NWLoTng2W0GQR1XS
NB5 NEnLUnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XSSGlEPTB;MUOuOFA3PyEQvF2= MmTmV2FPT0WU
SNU-387 NYLuOYp{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWqyUGxXUUN3ME2xN{42ODd{IN88US=> NVvNW5ZvW0GQR1XS
CAL-120 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVr4RXRvUUN3ME2xN{43PzF6IN88US=> NYrtTXJ[W0GQR1XS
Mo-T MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLYN|VKSzVyPUGzMlcxPyEQvF2= MmX3V2FPT0WU
LNCaP-Clone-FGC MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHuxUFhKSzVyPUGzMlc6QTJizszN M{DWcXNCVkeHUh?=
CAN MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3TR2pKSzVyPUG0MlAzQDhizszN NUHLdHJKW0GQR1XS
SK-MEL-30 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDDTWM2OD1zND6wOlMh|ryP MorCV2FPT0WU
COLO-678 NVLPUWJIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHBZoxWUUN3ME2xOE4xQDJ{IN88US=> MX3TRW5ITVJ?
SCC-9 Mn[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFy5VplKSzVyPUG0MlExOjFizszN M{ixb3NCVkeHUh?=
KINGS-1 NV7JdGdmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;FcG5KSzVyPUG0MlE1ODJizszN MYfTRW5ITVJ?
SL-513 NYD1S4RjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTF2LkG4O{DPxE1? MmTHV2FPT0WU
HLE MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTF2LkO4OVIh|ryP NInFPHdUSU6JRWK=
SW1573 NIj0S4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2Lw[2lEPTB;MUSuOFQ{PSEQvF2= NWPhVIRxW0GQR1XS
KYSE-140 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;4TWM2OD1zND62N|I4KM7:TR?= M3v3e3NCVkeHUh?=
SK-PN-DW M4\FNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLieHZJUUN3ME2xOE45ODBzIN88US=> NEfm[oZUSU6JRWK=
A253 NGPhS|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTF3LkC2NlUh|ryP MUHTRW5ITVJ?
CAL-12T MmC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnwXnRKSzVyPUG1MlQ3PjJizszN NV;Xfo5TW0GQR1XS
COLO-679 MnXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1W4U2lEPTB;MUWuO|Y5OyEQvF2= MWLTRW5ITVJ?
UACC-257 MoP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHznbY5KSzVyPUG2MlEzODFizszN MVHTRW5ITVJ?
U-87-MG NHLGXJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPVVlVKSzVyPUG2MlM2OjNizszN NEP6TppUSU6JRWK=
HCC1806 M1jjUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mon3TWM2OD1zNj63NFcyKM7:TR?= Ml\rV2FPT0WU
NCI-H2170 NEDsfG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTF5LkK0OFgh|ryP Mke5V2FPT0WU
AGS M3LsNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTF5LkO4NFgh|ryP M376OHNCVkeHUh?=
MEL-HO MlnCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTF5Lke1NFMh|ryP M4D5[XNCVkeHUh?=
SW48 MmrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoW0TWM2OD1zNz63O|E3KM7:TR?= NWrTdXY4W0GQR1XS
HuP-T4 M1XSXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGn0O3RKSzVyPUG4MlAzODZizszN M1n4[nNCVkeHUh?=
NCI-H720 NEnrZpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoriTWM2OD1zOD6xOFAzKM7:TR?= M{XKPHNCVkeHUh?=
RCC10RGB MmPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPXTWM2OD1zOD6xOlk4KM7:TR?= NIPpR5BUSU6JRWK=
HD-MY-Z MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\hSmlEPTB;MUiuNlI2PCEQvF2= NYHhbXk2W0GQR1XS
A427 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1m3fGlEPTB;MUiuOVA6PCEQvF2= NYDmWHBpW0GQR1XS
HCC2998 M2\wV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLRXXRPUUN3ME2xPE43ODVzIN88US=> MljKV2FPT0WU
EPLC-272H NUX1TppJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjjR|h7UUN3ME2xPU4xPDN2IN88US=> Mn7aV2FPT0WU
C32 NUDMPGlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1K1V2lEPTB;MUmuNFQ2KM7:TR?= NIT3cHNUSU6JRWK=
UMC-11 NGfLfJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofpTWM2OD1zOT6yNVI{KM7:TR?= M1L6dXNCVkeHUh?=
CaR-1 M1fSO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfRWFlKSzVyPUG5MlY5ODRizszN NWH1clhJW0GQR1XS
KYSE-410 NUW2THlET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nNWWlEPTB;MUmuPVE{QSEQvF2= NHribndUSU6JRWK=
HuCCT1 NUPxOng6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGG1[XRKSzVyPUKwMlYzQTRizszN MVvTRW5ITVJ?
LB996-RCC Mn63S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHxfWJbUUN3ME2yNE44OTZ6IN88US=> M1fpb3NCVkeHUh?=
KYSE-70 M4jwd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4C5[GlEPTB;MkCuPFA2QSEQvF2= NXTIZmRVW0GQR1XS
CAL-72 M4fD[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TGdWlEPTB;MkCuPVE2KM7:TR?= NXntfoJLW0GQR1XS
Capan-2 M2LnTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnJTWM2OD1{MT6wOFE{KM7:TR?= M3nhVXNCVkeHUh?=
PANC-08-13 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnw[25KSzVyPUKxMlI2OTVizszN M4OzXHNCVkeHUh?=
SBC-1 NEfz[o9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTJzLkOwPFEh|ryP NXnyTHliW0GQR1XS
MFM-223 M4\WOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4j0dmlEPTB;MkGuN|M1OiEQvF2= M4fQZ3NCVkeHUh?=
BB49-HNC Ml;PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nCTGlEPTB;MkGuOVcyPiEQvF2= M4\FUHNCVkeHUh?=
SH-4 NWf5S5M4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkThTWM2OD1{MT62OlE5KM7:TR?= M1;ONXNCVkeHUh?=
HuO9 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTJzLkm4NlUh|ryP NYPNZVZ5W0GQR1XS
AM-38 NUfxb3F2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnr2TWM2OD1{Mj6wOFg2KM7:TR?= MkHUV2FPT0WU
A431 NVu3fXdoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTJ|LkKxNVkh|ryP MlftV2FPT0WU
YAPC M4fsR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTJ|LkK2OVEh|ryP MkDiV2FPT0WU
LU-139 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTzfpBKSzVyPUKzMlQ5ODlizszN MmDMV2FPT0WU
HEC-1 MnnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTIPGhrUUN3ME2yN{41QTN5IN88US=> NYrEUFBoW0GQR1XS
SCC-25 NUi3fI5oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTJ2LkOwNFYh|ryP MmflV2FPT0WU
HT-29 M{XTOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX71cpNYUUN3ME2yOE4{QDJ|IN88US=> MWnTRW5ITVJ?
PC-14 M1fEN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTJ2Lk[1O|Eh|ryP NV3XXpRJW0GQR1XS
Calu-6 NHLhco5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTJ3LkWwO|Eh|ryP MXfTRW5ITVJ?
SJRH30 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzRTWM2OD1{NT62OFk3KM7:TR?= NV3G[GxlW0GQR1XS
ChaGo-K-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTJ4LkG2Nlkh|ryP NUHRfGFvW0GQR1XS
IA-LM NVnuN5hET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGWze3BKSzVyPUK2MlM3PDVizszN NUj6foRIW0GQR1XS
GP5d M1XvZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PtVGlEPTB;Mk[uOFQ6OSEQvF2= NFXGZ4tUSU6JRWK=
NCI-H2291 M4LKcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHwbJNKSzVyPUK2MlY2PDFizszN NV\4XWlbW0GQR1XS
BALL-1 M4X5V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknmTWM2OD1{Nj65N|k4KM7:TR?= M1PzfHNCVkeHUh?=
HCC1954 MkL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPpbFhKSzVyPUK2Mlk5ODhizszN NELPcFZUSU6JRWK=
NCI-H2452 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XFSmlEPTB;MkeuOFE3OyEQvF2= MYXTRW5ITVJ?
LU-99A NHzhR3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLkTWM2OD1{Nz61OVgzKM7:TR?= M2XJbXNCVkeHUh?=
NTERA-S-cl-D1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPMUWlxUUN3ME2yO{44Ojl7IN88US=> MXTTRW5ITVJ?
PANC-10-05 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrNTWM2OD1{Nz63O|c2KM7:TR?= MYTTRW5ITVJ?
NCI-H2405 NVvDSlBPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknKTWM2OD1{Nz65N|g4KM7:TR?= MojXV2FPT0WU
MDA-MB-415 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPFTWM2OD1{OD60NVM4KM7:TR?= Mmi4V2FPT0WU
NCI-H2342 M3X4fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nlXGlEPTB;MkiuOVI5OSEQvF2= MWfTRW5ITVJ?
TGBC24TKB M1fKOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofJTWM2OD1{OD63NVE4KM7:TR?= MVrTRW5ITVJ?
LU-134-A NHrERlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTJ6LkmyOlEh|ryP MlvHV2FPT0WU
SCC-4 NV3RNnRjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjWdYJKSzVyPUOxMlA1QTRizszN M{HBbHNCVkeHUh?=
Saos-2 MlLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHzTWM2OD1|MT65N|A3KM7:TR?= MkTKV2FPT0WU
RERF-LC-MS M1v6cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DzV2lEPTB;M{KuPFI{OSEQvF2= NHLmcVlUSU6JRWK=
M14 M4PJdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDkW|g3UUN3ME2zNk46PzZ2IN88US=> NYT3dVM3W0GQR1XS
HPAF-II M1SzbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\XOpNKSzVyPUOzMlUxOTFizszN MWXTRW5ITVJ?
NCI-H1755 NH\xd5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\pXGlEPTB;M{SuN|MxPSEQvF2= M1HxTnNCVkeHUh?=
D-392MG M3TuZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PpfWlEPTB;M{WuPFY4PCEQvF2= M13ZVXNCVkeHUh?=
A704 MorSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYqyfJRRUUN3ME2zOk4xPDJ5IN88US=> NXWzenpvW0GQR1XS
CP50-MEL-B M1[3NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG[5eY9KSzVyPUO2MlE6OTFizszN MVLTRW5ITVJ?
EW-18 NYnU[5RjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFO0VGdKSzVyPUO2MlQ2OiEQvF2= MoHFV2FPT0WU
WM-115 M4DzR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTN4LkiwPVkh|ryP NXf5WoxCW0GQR1XS
LU-65 M3;ISGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3kS2RDUUN3ME2zO{4yPDF5IN88US=> M1XZTHNCVkeHUh?=
NCI-H1563 M1L2T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfIOJRKSzVyPUO3MlI1QDRizszN NFGwNo9USU6JRWK=
DBTRG-05MG NWDuO3A3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjPTWM2OD1|OD6wOlkyKM7:TR?= MmrRV2FPT0WU
NCI-H630 NEXrfnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7wWlNxUUN3ME2zPE41PzF2IN88US=> MlLPV2FPT0WU
NCI-H1155 NYLnbJY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTN7LkK0NkDPxE1? NXPVSW41W0GQR1XS
OVACR-3 M4rTcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTN7LkmxPVUh|ryP NVHTcJdiW0GQR1XS
OAW-42 MmnjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLQTWM2OD12MD60NlU5KM7:TR?= M13SUnNCVkeHUh?=
JVM-2 NF7zXnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTRzLkK0NVUh|ryP MlzQV2FPT0WU
C3A Mnn1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjDOHhkUUN3ME20NU4{PDR5IN88US=> NUHGfmlVW0GQR1XS
HT55 NYC5UotET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPWS4FQUUN3ME20Nk4zQDRzIN88US=> NFSyWFJUSU6JRWK=
OVCAR-4 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknKTWM2OD12Mj6yPVc1KM7:TR?= M1zoUHNCVkeHUh?=
MEG-01 M3;BWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEm3XYRKSzVyPUSyMlQ3OTZizszN NFX4WXVUSU6JRWK=
NCI-H82 MoHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDzb49pUUN3ME20N{46QDl{IN88US=> NIrxdZFUSU6JRWK=
JEG-3 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkflTWM2OD12ND65OFch|ryP NF;sW5JUSU6JRWK=
BPH-1 M4ewcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTR4LkO5PVgh|ryP MojRV2FPT0WU
MPP-89 NV7aXHQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIm4VJRKSzVyPUS3MlI5QThizszN NH7xV4RUSU6JRWK=
ALL-PO NFfN[WZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELKfldKSzVyPUS3MlQyQDhizszN MmTKV2FPT0WU
HT Ml7tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYC5N5NbUUN3ME20O{41QTJizszN M4S3bHNCVkeHUh?=
NCI-H2347 MofSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3S1U2lEPTB;NEiuNFcyPSEQvF2= M{TheXNCVkeHUh?=
A2780 NGLmVopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWq1bY5PUUN3ME20PU41OjJ6IN88US=> NUfZOWNtW0GQR1XS
KARPAS-299 NEDoc4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVftW25CUUN3ME20PU42OTF7IN88US=> NXHlfGFHW0GQR1XS
NCI-H1651 NVTH[oFZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnVVJhRUUN3ME20PU45QDJzIN88US=> NX[5U5FGW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo PD 0332991 indicates complete tumor stasis in a MDA-MB-435 xenograft at 150 mg/kg. PD 0332991 also shows broad-spectrum antitumor activity in multiple human tumor xenografts by eliminating phospho-Rb and the proliferative marker Ki-67 from tumor tissue and down-regulation of genes under the transcriptional control of E2F. [1]

Protocol

Kinase Assay:[1]
+ Expand

Cdk Assays:

A stock solution of PD0332991 is prepared in DMSO. CDK assays are performed in 96-well filter plates. All CDK-cyclin kinase complexes are expressed in insect cells through baculovirus infection and purified. The substrate for the assays is a fragment (amino acids 792–928) of pRb fused to GST (GST·RB-Cterm). The total volume in each well is 0.1 mL containing a final concentration of 20 mM Tris-HCl, pH 7.4, 50 mM NaCl, 1 mM dithiothreitol, 10 mM MgCl2, 25 μM ATP (for CDK4-cyclin D1, CDK6-cyclin D2, and CDK6-cyclin D3) or 12 μM ATP (for CDK2-cyclin E, CDK2-cyclin A, and CDC2-cyclin B) containing 0.25 μCi of [γ-32P]ATP, 20 ng of enzyme, 1 μg of GST·RB-Cterm, and PD 0332991 (0.001-0.1μM). All components except the [γ-32P]ATP are added to the wells, and the plate is placed on a plate mixer for 2 min. The reaction is started by adding the [γ-32P]ATP and the plate is incubated at 25 °C for 15 min. The reaction is terminated by addition of 0.1 mL of 20% trichloroacetic acid and the plate is kept at 4  °C for at least 1 hour to allow the substrate to precipitate. The wells are then washed 5 times with 0.2 mL of 10% trichloroacetic acid and radioactive incorporation is determined with a β plate counter.
Cell Research:[1]
+ Expand
  • Cell lines: Tumor cell lines including MDA-MB-435, ZR-75-1, T-47D, MCF-7, H1299, Colo-205, MDA-MB-468, H2009, CRRF-CEM and K562
  • Concentrations: 0.01-1 μM
  • Incubation Time: 24 hours
  • Method: Cells are seeded at 2 × 104 per well in a 96-well plate and incubated overnight. PD 0332991 (0.01-1 μM) is added to the wells and incubated at 37 °C for another 24 hours. [14C]Thymidine (0.1 μCi) is added to each well and incorporation of the radiolabel is allowed to proceed for 72 hours. Incorporated radioactivity is determined with a β plate counter.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: Advanced stage human tumor xenografts including Colo-205, MDA-MB-435 breast, SF-295 glioblastoma, ZR-75-1 breast, PC-3 prostate, H125 lung, SW-620 colon, H23 lung and MDA-MB-468 breast (Rb negative) are established in severe combined immunodeficient mice.
  • Formulation: Dissolved in sodium lactate buffer (50 mM, pH 4.0)
  • Dosages: 0-150 mg/kg
  • Administration: Given by gavage
    (Only for Reference)

Solubility (25°C)

In vitro Water 30 mg/mL (61.98 mM)
DMSO 3 mg/mL warmed (6.19 mM)
Ethanol <1 mg/mL
In vivo Saline 20 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 483.99
Formula

C24H29N7O2.HCl

CAS No. 827022-32-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03007979 Not yet recruiting Breast Cancer|Breast Carcinoma|Cancer of Breast|Malignant Tumor of Breast Washington University School of Medicine February 28, 2017 Phase 2
NCT02907918 Not yet recruiting Breast Cancer|Cancer of Breast|Breast Carcinoma Washington University School of Medicine|Pfizer February 28, 2017 Phase 2
NCT01209598 Completed Sarcoma|Liposarcoma Memorial Sloan Kettering Cancer Center|Pfizer September 23, 2010 Phase 2
NCT03054363 Not yet recruiting Breast Cancer University of Colorado, Denver March 2017 Phase 1|Phase 2
NCT03024489 Not yet recruiting Head and Neck Cancer|Locally Advanced|Unresectable Mahidol University February 2017 Phase 1|Phase 2
NCT02947685 Not yet recruiting HER-2 Positive Breast Cancer|Estrogen Receptor Positive Breast Cancer Alliance Foundation Trials, LLC.|Pfizer|German Breast Group (GBG)|Fondazione Michelangelo|PrECOG, LLC.|The Australia and New Zealand Breast Cancer Trials Group (ANZBCTG)|Alliance Foundation Trials Biorepository - Washington State University|Alliance Foundation Trials Central Imaging Core Lab - Ohio State University|Mastering Breast Cancer Initiative, LLC|Mayo Clinic Statistics and Data Center|INC Research|SOLTI Breast Cancer Research Group February 2017 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

CDK Signaling Pathway Map

CDK Inhibitors with Unique Features

Related CDK Products

Tags: buy Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl supplier | purchase Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl cost | Palbociclib (PD-0332991) HCl manufacturer | order Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID